JENKINS GEORGE M 4

What Happened

George M. Jenkins, a director of Palvella Therapeutics, received a grant/award covering 3,000 shares (reported as a derivative security) on 2026-06-10. The reported acquisition price is $0.00, so no cash was paid; the award is subject to vesting and is typical of director compensation rather than an open-market purchase or sale.

Key Details

• Transaction date and price: 2026-06-10; 3,000 shares @ $0.00 (derivative award).
• Shares owned after transaction: Not specified in the Form 4 provided.
• Vesting/footnote: The award “shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the issuer’s next annual meeting of stockholders,” subject to continued service (per footnote F1).
• Filing timeliness: Report filed 2026-06-12 (two days after the transaction) — appears timely under Form 4 rules.

Context

This was a compensation-related equity grant to a director, not a cash purchase or sale. Because the shares/options vest in the future and no sale occurred, there is no immediate market signal of insider buying or selling. Small award size (3,000 shares) is common for board compensation; investors should treat this as routine director compensation rather than an explicit endorsement of near-term stock moves.